Please wait while the formulary information is being retrieved.
ESBRIET (PIRFENIDONE)
- Idiopathic pulmonary fibrosis
267 mg tablet
- 3 tablets (801 mg) by oral route 3 times per day at the same times each day
801 mg tablet
- 1 tablet (801 mg) by oral route 3 times per day at the same times each day
267 mg capsule
- 3 capsules (801 mg) by oral route 3 times per day at the same times each day
Idiopathic pulmonary fibrosis
- 1 capsule (267 mg) by oral route 3 times per day at the same times each day on days 1 through 7 of treatment
- 1 tablet (267 mg) by oral route 3 times per day at the same times each day on days 1 through 7 of treatment
- 2 capsules (534 mg) by oral route 3 times per day at the same times each day on days 8 through 14 of treatment
- 2 tablets (534 mg) by oral route 3 times per day at the same times each day on days 8 through 14 of treatment
- 3 capsules (801 mg) by oral route 3 times per day at the same times each day
- 3 tablets (801 mg) by oral route 3 times per day at the same times each day
- 1 tablet (801 mg) by oral route 3 times per day at the same times each day
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- fluvoxamine
- Luvox Cr
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Abnormal hepatic function tests
- Gastroesophageal reflux disease
- Tobacco smoker
Severe
Moderate
- None
ESBRIET (PIRFENIDONE)
- Idiopathic pulmonary fibrosis
- None
- Acute abdominal pain
- Arthralgias
- Diarrhea
- Dizziness
- Dyspepsia
- Fatigue
- Gastroesophageal reflux disease
- Headache disorder
- Insomnia
- Nausea
- Sinusitis
- Skin rash
- Upper respiratory infection
- Vomiting
- Weight loss
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Increased alanine transaminase
- Increased aspartate transaminase
- Anorexia
- Dysgeusia
- Non-cardiac chest pain
- Pruritus of skin
- Skin photosensitivity
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Agranulocytosis
- Angioedema
- Drug-induced hepatitis
- Hyperbilirubinemia
- Neutropenic disorder
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pirfenidone
Safety and efficacy not established,
- 1 Day – 18 Years
- Safety and efficacy not established,
Pirfenidone
- Severity Level:
2
- Additional Notes: Insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Pirfenidone
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Pirfenidone
Renal-Use caution and monitor more closely for adverse effects with CrCl<81 mL/min. Though AUCs ranged from 1.2-1.5x higher in this CrCl range, the manufacturer states that the dosage may require adjustment.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Idiopathic pulmonary fibrosis | |
| J84.112 | Idiopathic pulmonary fibrosis |
| 0-9 | A-Z |
|---|---|
| J84.112 | Idiopathic pulmonary fibrosis |
Formulary Reference Tool